Statin Use Improves Overall Survival of Patients with Gastric Cancer after Surgery and Adjuvant Chemotherapy in Taiwan: A Nationwide Matched Cohort Study

Background: Numerous studies have revealed that statins have antitumor effects in vivo and in vitro. However, few studies have explored the relationship between statin use and the mortality of gastric cancer (GC) patients after treatments. This study examines the relationship between statin use and...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2020-08, Vol.12 (8), p.2055
Main Authors: Yang, Pei-Rung, Tsai, Ying-Ying, Chen, Ko-Jung, Yang, Yao-Hsu, Shih, Wei-Tai
Format: Article
Language:English
Subjects:
Angiogenesis
Antitumor activity
Apoptosis
Cancer
Cancer therapies
Care and treatment
Cell division
Chemotherapy
Cholesterol
Cohort analysis
Drug dosages
Gastric cancer
Health aspects
Medical prognosis
Mortality
Patient outcomes
Population
Radiation therapy
Regression analysis
Sensitivity analysis
Statins
Stomach cancer
Studies
Surgery
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Numerous studies have revealed that statins have antitumor effects in vivo and in vitro. However, few studies have explored the relationship between statin use and the mortality of gastric cancer (GC) patients after treatments. This study examines the relationship between statin use and the overall survival (OS) of GC patients after surgery and adjuvant chemotherapy, using data from the nationwide cohort database of Taiwan. Methods: All patients newly diagnosed with GC from 1999 to 2008 in Taiwan were identified from the Registry of Catastrophic Illness Patients Database. Through propensity score matching, statin users were matched to statin non-users at a 1:4 ratio. The relationship between statin use and the OS of patients with GC was estimated through Cox regression models. Results: The study cohort included 1835 patients with GC who had received therapies during the study period. The death numbers among statin users (defined as those who used more than 28 cumulative defined daily doses (cDDDs)) and statin non-users were 138 and 895, respectively. A dose–response association was noted between statin use and the OS of patients with GC after treatments. The adjusted hazard ratios were 0.62 (95% confidence intervals (CI), 0.50–0.78) and 0.34 (95% CI, 0.26–0.45) for statin users administered 28–167 cDDDs and >168 cDDDs, respectively, compared with no statin use (
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers12082055